AD (Alzheimer's disease) is characterized by a progressive and devastating mental decline that is usually presaged by impairment of a form of memory dependent on medial temporal lobe structures, including the hippocampus. The severity of clinical dementia correlates positively with the cerebral load of the AD-related protein Aβ (amyloid β), particularly in its soluble form rather than the insoluble fibrillar Aβ found in amyloid plaques. Recent research in animal models of AD has pointed to a potentially important role for rapid disruptive effects of soluble species of Aβ on neural function in causing a relatively selective impairment of memory early in the disease. Our experiments assessing the mechanisms of Aβ inhibition of LTP (long-term potentiation), a correlate of memory-related synaptic plasticity, in the rodent hippocampus showed that lown oligomers were the soluble Aβ species primarily responsible for the disruption of synaptic plasticity in vivo. Exogenously applied and endogenously generated anti-Aβ antibodies rapidly neutralized and prevented the synaptic plasticity disrupting effects of these very potent Aβ oligomers. This suggests that active or passive immunotherapeutic strategies for early AD should target Aβ oligomers in the brain. The ability of agents that reduce nitrosative/oxidative stress or antagonize stress-activated kinases to prevent Aβ inhibition of LTP in vitro points to a key role of these cellular mechanisms at very early stages in Aβ-induced neuronal dysfunction. A combination of antibody-mediated inactivation of Aβ oligomers and pharmacological prevention of cellular stress mechanisms underlying their synaptic plasticity disrupting effects provides an attractive strategy in the prevention of early AD.
Introduction
Aβ (amyloid β) protein has been proposed to be the primary cause of both familial and sporadic forms of AD (Alzheimer's disease) [1, 2] . Aβ is a product of the cleavage of the transmembrane protein APP (β-amyloid precursor protein) by two enzymatic steps. After a large N-terminus of APP is removed by β-secretase (BACE1), the remaining APP stub is cleaved within the membrane by the γ -secretase complex (including Presenilin, Aph-1, Pen-2 and Nicastrin) [3] to release Aβ of varying lengths, predominantly Aβ40 and Aβ42. Point mutations at or near these sites of APP cleavage, which cause an autosomal dominant early onset familial AD, increase the relative production of Aβ42. Aβ42 is particularly prone to self-association [4] and is also much more toxic to neurons than Aβ40. In sporadic late-onset AD, an age-dependent accumulation of Aβ, caused by increased production and a reduction of Aβ clearance, coupled to an age-dependent diminished cellular protective reserve, has been implicated [5] [6] [7] .
One of the key issues currently being addressed is the determination of the assembly state of Aβ that may be res-ponsible for the cognitive decline in AD. Although Aβ fibrils are the main components of the hallmark neuropathological plaque lesions, including neuritic plaques where dystrophic neuronal processes are detected, the amount of these relatively insoluble Aβ assemblies correlates relatively poorly with cognitive status at the time of death of the patient [8, 9] . A much stronger positive correlation of soluble Aβ species and dementia severity has been reported [10] [11] [12] . Consistent findings have been obtained in transgenic mouse models of AD where cognitive impairment can be observed long before fibrillar Aβ is detectable [13] [14] [15] . The more soluble Aβ species include monomers, low-n oligomers and large oligomers. An emerging picture from our study and those of others is that oligomeric Aβ is a major contributor to cognitive deficits in AD, particularly at the early stage [16] [17] [18] [19] .
Aβ species disrupting hippocampal synaptic plasticity in vivo
The hippocampus is very sensitive to a wide variety of insults and there is preclinical evidence of hippocampal shrinkage in people with familial AD and people with mild cognitive impairment who subsequently develop sporadic AD [20] [21] [22] [23] . Before the clinical diagnosis of dementia, people with both familial and sporadic AD usually have impaired episodic (personal history) memory, a form of memory that is dependent on the medial temporal lobe, including the entorhinal cortex and hippocampus [21, 22, 24] . Hippocampus-dependent memory is believed to be mediated physiologically by activity-dependent persistent changes in synaptic efficacy [25] . Brief high-frequency conditioning electrical stimulation of afferent fibres in the rodent hippocampus is used to induce LTP (long-term potentiation), an increase in fast excitatory glutamatergic synaptic transmission that can last for several months. Some years ago, we discovered that synthetic Aβ potently inhibited the induction of LTP in vivo, particularly the longer lasting 'late-phase LTP', at doses and times that did not affect baseline excitatory synaptic transmission [26] . More recently, we examined the nature of the responsible Aβ species [27] [28] [29] .
In one series of experiments, we compared the ability of wild-type and mutant synthetic Aβ40 to inhibit LTP at CA1 synapses in urethane-anaesthetized rats [28] . Two naturally occurring point mutations of APP that cause an amino acid substitution at position 22 of Aβ were examined. In one mutant Aβ, the Arctic peptide, glutamic residue is replaced by glycine residue, and in the other, the Dutch peptide, glutamine is the substitute amino acid. Both of these Aβ mutants oligomerize to form protofibrils and fibrils more easily than wildtype Aβ [30] [31] [32] . However, patients with the Arctic APP mutation develop an insidious early onset dementia with AD neuropathology, whereas patients with the Dutch mutation develop cerebrovascular haemorrhages and dementia with extensive vascular amyloid deposition. I.c.v. (intracerebroventricular) injection of soluble Aβ inhibited LTP with an order of potency of Arctic > Dutch > > wild-type Aβ. The extremely high potency of the soluble Arctic peptide, both in absolute terms (5 pmol i.c.v.) and relative to the Dutch (∼50 pmol) but especially the wild-type (>500 pmol) Aβ peptide, points to a key role of soluble Aβ in causing early AD-like pathophysiology.
In a separate series of experiments, we examined the role of different soluble Aβ species using naturally secreted nonfibrillar Aβ ( Figure 1 ) [27, 29] . Chinese-hamster ovary cells were transfected with a familial AD-linked human mutant APP (Indiana mutation; valine to phenylalanine at position 717, near the γ -secretase site). The conditioned medium from these cells (called 7PA2 cells) contains low nanomolar concentrations of Aβ, primarily consisting of monomers and some low-n oligomers. Injection of this medium i.c.v. mimicked the inhibitory effect of synthetic Aβ on LTP induction. We then used a strategy of selectively reducing the amount of Aβ monomers in the medium by addition of an insulindegrading enzyme and of Aβ oligomers by preincubation with a relatively low concentration of a γ -secretase inhibitor. Whereas the Aβ monomer-depleted medium maintained its ability to inhibit LTP, the Aβ oligomer-depleted medium failed to affect LTP. These findings led us to conclude that the low-n oligomeric Aβ, primarily dimers and trimers, causes the inhibition of LTP by Aβ.
Further support for this conclusion was provided by our use of size-exclusion chromatography of the conditioned medium from 7PA2 cells to separate the different Aβ species. An oligomer-enriched fraction of the medium was a highly effective inhibitor of LTP induction when injected i.c.v., whereas a fraction enriched with Aβ monomers was without effect. Consistent findings have been reported in vitro [33] [34] [35] . In the latter study, anti-fibrillogenesis agents that inhibited the formation of soluble oligomers by 7PA2 cells prevented the inhibition of LTP by 7PA2-conditioned medium.
Antibodies against Aβ can directly neutralize the synaptic plasticity disrupting Aβ oligomers in the brain
As a corollary to our discovery of the key role of Aβ oligomers in mediating the inhibition of LTP in vivo, we tested the ability of exogenously applied and endogenously generated anti-Aβ antibodies to prevent the inhibitory effect of naturally secreted Aβ [29] .
Active immunization using Aβ as an immunogen has been found to trigger the removal of fibrillar Aβ in plaques in transgenic mouse models [36] and also possibly in patients with AD [37, 38] . However, the ability to prevent the memory impairment seen in some of the animal models was not accompanied by a parallel decrease in total Aβ brain levels [39] . Passive systemic immunization and direct intracerebral injections of antibodies to Aβ indicate that there are several potential mechanisms of action of anti-Aβ antibodies, including microglia-mediated clearance, which takes several days, and potentially more rapid microglia-independent routes [40] [41] [42] [43] . Amongst the latter, there is growing evidence that plasma antibodies can act as a 'peripheral sink' for brain Aβ and thereby reduce cerebral Aβ load [44] . Intriguingly, a single administration of antibody caused a rapid behavioural improvement without any detectable change in brain Aβ burden as measured by immunohistochemistry [45] . These and similar findings led to the proposal that at least some of the beneficial effects of anti-Aβ antibodies may be due to a direct scavenging of those diffusible Aβ species responsible for the disruption of memory [45, 46] .
Co-injection i.c.v. of the Aβ-containing medium and a monoclonal antibody that could immunoprecipitate Aβ oligomers (6E10), 10 min before the application of high-frequency conditioning stimulation, completely abrogated the inhibition of LTP induction ( Figure 1A) . Boiled 6E10 or an isotype control antibody, 9E10, were without effect on the inhibition of LTP. Since 6E10 recognizes the N-terminus of Aβ, we also examined a monoclonal antibody to the midregion of Aβ, 4G8, and obtained similar results. Moreover, when 6E10 was injected after the administration of the Aβ-containing medium, normal LTP was induced by the conditioning stimulation ( Figure 1B) . We also co-injected 6E10 with the Aβ oligomer-enriched fraction produced by sizeexclusion chromatography. Again the inhibition of LTP was prevented.
These findings provide very strong experimental evidence that antibodies to Aβ can rapidly neutralize the synaptic plasticity-disrupting low-n oligomers of Aβ directly in the brain. Thus the apparent paradox that antibodies to Aβ can rapidly reverse the memory deficits in transgenic mouse models of AD without reducing brain Aβ burden [45, 46] can be explained by such a mechanism. It is likely that in addition to direct scavenging in the cerebrospinal fluid, antibodies reach the interstitial fluid in brain regions such as the hippocampus [40, 47] where Aβ oligomers can be neutralized before they disrupt synaptic plasticity mechanisms underlying memory formation.
The recent clinical trial of active vaccination with preaggregated Aβ42 in mild to moderate AD was terminated prematurely due to the development of meningoencephalitis in a subgroup [48] . Preliminary findings indicated that the induction of antibodies that bound Aβ fibrils, but not monomers, was related to a possible protection of cognitive function, including a hippocampus-dependent task [49] . We therefore went on to determine if vaccination of rats with a mixture of preaggregated Aβ40 and Aβ42 could prevent the inhibition of LTP induction by naturally produced soluble Aβ ( Figure 1A ) [29] . Vaccinated animals that were successfully immunized, as indicated by the presence of plasma antibodies measured by ELISA or immunoprecipitation of Aβ from the 7PA2-conditioned medium, were partially protected from the inhibition of LTP. Importantly, those animals with plasma antibodies with a moderate to strong ability to immunoprecipitate Aβ dimers and trimers were the ones partially resistant to the blocking of LTP. In contrast, animals with relatively high titres that bound plaque Aβ or recognized Aβ monomers but not oligomers were not protected. Thus endogenously generated antibodies with the ability to bind Aβ low-n oligomers can also neutralize the synaptic plasticity disrupting effect of natural Aβ.
Conclusion
The research described here raises the possibility of a reversible component of the cognitive deficits in early AD that might be rapidly affected by targeting the active (oligomeric) Aβ species. It would be interesting to determine if any of the successfully immunized patients with mild to moderate AD in the prematurely terminated active vaccination clinical trial generated anti-Aβ antibodies that recognized Aβ oligomers. Whether or not such patients would show a rapid improvement in cognition is of considerable interest since they would be expected to also have extensive tau-related neuropathology.
We have also carried out extensive studies into the cellular mechanisms mediating the Aβ inhibition of LTP at medial perforant path synapses with dentate gyrus granule cells in hippocampal slices in vitro [19, 34, 50] . Agents that reduce nitrosative/oxidative stress, such as inducible nitric oxide synthase inhibitors and superoxide dismutase, or antagonize stress-activated kinases, including p38 mitogen-activated protein kinase and c-Jun N-terminal kinase, prevented the inhibition of LTP, as did minocycline, a clinically tested tetracycline antibiotic derivative which also inhibits microglial activation and is known to readily penetrate the central nervous system. These findings point to a key role of activation of cellular-stress mechanisms at very early stages of soluble Aβ-induced neuronal dysfunction in addition to their more established role in the cytotoxicity of high concentrations of fibrillar Aβ. We have already proposed a model in which acute synaptic plasticity disruption by Aβ oligomers may gradually cause at least some of the synaptic loss that is observed in chronic animal models and in patients with clinical AD [19] . Perhaps by combining antibody-based therapy that includes direct neutralization of Aβ oligomers in the brain with pharmacotherapy that prevents excessive activation of cellular stress by these oligomers it will be possible to break a key link in the insidious progression of cognitive decline in AD.
